Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Status:
Completed
Trial end date:
2016-03-15
Target enrollment:
Participant gender:
Summary
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the
Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor
malignancies.